175 related articles for article (PubMed ID: 27355874)
1. Discovery of a Highly Selective Glycogen Synthase Kinase-3 Inhibitor (PF-04802367) That Modulates Tau Phosphorylation in the Brain: Translation for PET Neuroimaging.
Liang SH; Chen JM; Normandin MD; Chang JS; Chang GC; Taylor CK; Trapa P; Plummer MS; Para KS; Conn EL; Lopresti-Morrow L; Lanyon LF; Cook JM; Richter KE; Nolan CE; Schachter JB; Janat F; Che Y; Shanmugasundaram V; Lefker BA; Enerson BE; Livni E; Wang L; Guehl NJ; Patnaik D; Wagner FF; Perlis R; Holson EB; Haggarty SJ; El Fakhri G; Kurumbail RG; Vasdev N
Angew Chem Int Ed Engl; 2016 Aug; 55(33):9601-5. PubMed ID: 27355874
[TBL] [Abstract][Full Text] [Related]
2. Structural Basis for Achieving GSK-3β Inhibition with High Potency, Selectivity, and Brain Exposure for Positron Emission Tomography Imaging and Drug Discovery.
Bernard-Gauthier V; Mossine AV; Knight A; Patnaik D; Zhao WN; Cheng C; Krishnan HS; Xuan LL; Chindavong PS; Reis SA; Chen JM; Shao X; Stauff J; Arteaga J; Sherman P; Salem N; Bonsall D; Amaral B; Varlow C; Wells L; Martarello L; Patel S; Liang SH; Kurumbail RG; Haggarty SJ; Scott PJH; Vasdev N
J Med Chem; 2019 Nov; 62(21):9600-9617. PubMed ID: 31535859
[TBL] [Abstract][Full Text] [Related]
3. 5-Aryl-4-carboxamide-1,3-oxazoles: potent and selective GSK-3 inhibitors.
Gentile G; Merlo G; Pozzan A; Bernasconi G; Bax B; Bamborough P; Bridges A; Carter P; Neu M; Yao G; Brough C; Cutler G; Coffin A; Belyanskaya S
Bioorg Med Chem Lett; 2012 Mar; 22(5):1989-94. PubMed ID: 22310227
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and evaluation of 8-amino-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives as glycogen synthase kinase-3 (GSK-3) inhibitors.
Chun K; Park JS; Lee HC; Kim YH; Ye IH; Kim KJ; Ku IW; Noh MY; Cho GW; Kim H; Kim SH; Kim J
Bioorg Med Chem Lett; 2013 Jul; 23(13):3983-7. PubMed ID: 23683591
[TBL] [Abstract][Full Text] [Related]
5. Computer-aided molecular design of pyrazolotriazines targeting glycogen synthase kinase 3.
Sciú ML; Sebastián-Pérez V; Martinez-Gonzalez L; Benitez R; Perez DI; Pérez C; Campillo NE; Martinez A; Moyano EL
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):87-96. PubMed ID: 30362380
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of a novel, orally active GSK-3 inhibitor 6-Methyl-N-[3-[[3-(1-methylethoxy)propyl]carbamoyl]-1H-pyrazol-4-yl]pyridine-3-carboxamide in tau transgenic mice.
Uno Y; Iwashita H; Tsukamoto T; Uchiyama N; Kawamoto T; Kori M; Nakanishi A
Brain Res; 2009 Nov; 1296():148-63. PubMed ID: 19698704
[TBL] [Abstract][Full Text] [Related]
7. The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor.
Capurro V; Lanfranco M; Summa M; Porceddu PF; Ciampoli M; Margaroli N; Durando L; Garrone B; Ombrato R; Tongiani S; Reggiani A
Biomed Pharmacother; 2020 Aug; 128():110249. PubMed ID: 32470749
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and evaluation of [(11)C]PyrATP-1, a novel radiotracer for PET imaging of glycogen synthase kinase-3β (GSK-3β).
Cole EL; Shao X; Sherman P; Quesada C; Fawaz MV; Desmond TJ; Scott PJ
Nucl Med Biol; 2014 Jul; 41(6):507-12. PubMed ID: 24768148
[TBL] [Abstract][Full Text] [Related]
9. Tau-Centric Multitarget Approach for Alzheimer's Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3β and Tau-Aggregation Inhibitors.
Gandini A; Bartolini M; Tedesco D; Martinez-Gonzalez L; Roca C; Campillo NE; Zaldivar-Diez J; Perez C; Zuccheri G; Miti A; Feoli A; Castellano S; Petralla S; Monti B; Rossi M; Moda F; Legname G; Martinez A; Bolognesi ML
J Med Chem; 2018 Sep; 61(17):7640-7656. PubMed ID: 30078314
[TBL] [Abstract][Full Text] [Related]
10. A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S )-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease.
Onishi T; Iwashita H; Uno Y; Kunitomo J; Saitoh M; Kimura E; Fujita H; Uchiyama N; Kori M; Takizawa M
J Neurochem; 2011 Dec; 119(6):1330-40. PubMed ID: 21992552
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of pyrimidin-4-one-1,2,3-triazole conjugates as glycogen synthase kinase-3β inhibitors with anti-depressant activity.
Khan I; Tantray MA; Hamid H; Alam MS; Kalam A; Hussain F; Dhulap A
Bioorg Chem; 2016 Oct; 68():41-55. PubMed ID: 27454617
[TBL] [Abstract][Full Text] [Related]
12. Discovery of Isonicotinamides as Highly Selective, Brain Penetrable, and Orally Active Glycogen Synthase Kinase-3 Inhibitors.
Luo G; Chen L; Burton CR; Xiao H; Sivaprakasam P; Krause CM; Cao Y; Liu N; Lippy J; Clarke WJ; Snow K; Raybon J; Arora V; Pokross M; Kish K; Lewis HA; Langley DR; Macor JE; Dubowchik GM
J Med Chem; 2016 Feb; 59(3):1041-51. PubMed ID: 26751161
[TBL] [Abstract][Full Text] [Related]
13. The first synthesis of [(11)C]SB-216763, a new potential PET agent for imaging of glycogen synthase kinase-3 (GSK-3).
Wang M; Gao M; Miller KD; Sledge GW; Hutchins GD; Zheng QH
Bioorg Med Chem Lett; 2011 Jan; 21(1):245-9. PubMed ID: 21115250
[TBL] [Abstract][Full Text] [Related]
14. 2-(2-Phenylmorpholin-4-yl)pyrimidin-4(3H)-ones; a new class of potent, selective and orally active glycogen synthase kinase-3β inhibitors.
Fukunaga K; Uehara F; Aritomo K; Shoda A; Hiki S; Okuyama M; Usui Y; Watanabe K; Yamakoshi K; Kohara T; Hanano T; Tanaka H; Tsuchiya S; Sunada S; Saito K; Eguchi J; Yuki S; Asano S; Tanaka S; Mori A; Yamagami K; Baba H; Horikawa T; Fujimura M
Bioorg Med Chem Lett; 2013 Dec; 23(24):6933-7. PubMed ID: 24176395
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of zinc-induced phosphorylation of p70 S6 kinase and glycogen synthase kinase 3beta in SH-SY5Y neuroblastoma cells.
An WL; Bjorkdahl C; Liu R; Cowburn RF; Winblad B; Pei JJ
J Neurochem; 2005 Mar; 92(5):1104-15. PubMed ID: 15715661
[TBL] [Abstract][Full Text] [Related]
16. Discovery of new acylaminopyridines as GSK-3 inhibitors by a structure guided in-depth exploration of chemical space around a pyrrolopyridinone core.
Sivaprakasam P; Han X; Civiello RL; Jacutin-Porte S; Kish K; Pokross M; Lewis HA; Ahmed N; Szapiel N; Newitt JA; Baldwin ET; Xiao H; Krause CM; Park H; Nophsker M; Lippy JS; Burton CR; Langley DR; Macor JE; Dubowchik GM
Bioorg Med Chem Lett; 2015 May; 25(9):1856-63. PubMed ID: 25845281
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of glycogen synthase kinase-3 reverses tau hyperphosphorylation induced by Pin1 down-regulation.
Xiong YS; Wang DL; Tan L; Wang X; Chen LM; Gong CX; Wang JZ; Zhu LQ
CNS Neurol Disord Drug Targets; 2013 May; 12(3):436-43. PubMed ID: 23469846
[TBL] [Abstract][Full Text] [Related]
18. Structure-based optimization of oxadiazole-based GSK-3 inhibitors.
Lo Monte F; Kramer T; Gu J; Brodrecht M; Pilakowski J; Fuertes A; Dominguez JM; Plotkin B; Eldar-Finkelman H; Schmidt B
Eur J Med Chem; 2013 Mar; 61():26-40. PubMed ID: 22749643
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation.
Selenica ML; Jensen HS; Larsen AK; Pedersen ML; Helboe L; Leist M; Lotharius J
Br J Pharmacol; 2007 Nov; 152(6):959-79. PubMed ID: 17906685
[TBL] [Abstract][Full Text] [Related]
20. Discovery of 2-(Anilino)pyrimidine-4-carboxamides as Highly Potent, Selective, and Orally Active Glycogen Synthase Kinase-3 (GSK-3) Inhibitors.
Hartz RA; Ahuja VT; Luo G; Chen L; Sivaprakasam P; Xiao H; Krause CM; Clarke WJ; Xu S; Tokarski JS; Kish K; Lewis H; Szapiel N; Ravirala R; Mutalik S; Nakmode D; Shah D; Burton CR; Macor JE; Dubowchik GM
J Med Chem; 2023 Jun; 66(11):7534-7552. PubMed ID: 37235865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
